The goal of the study is to examine the short-term effects and safety of eplerenone, a systemic anti-aldosterone medication, in a group of patients with central serous chorioretinopathy (CSCR).~There is currently no standard treatment or therapy for chronic CSCR, a potentially debilitating eye disease.~There is evidence that high blood serum corticosteroid levels can cause or worsen CSCR~Eplerenone, a mineralocorticoid receptor antagonist, has been shown to be of visual and anatomic benefit in a small series of 4 patients with chronic CSCR, suggesting that decreasing mineralocorticoid action in the eye may improve signs and symptoms of CSCR~The study's aim is to evaluate a standardized dose of eplerenone in a controlled prospective fashion for chronic CSCR.~The study consists of taking a standard dose of eplerenone, 25mg once daily for a week, followed by 50mg once daily, for a total of 3 months~Patients will be monitored for efficacy and side effects from the beginning of treatment and for 6 months
The aim of the study is to determine the efficacy and safety in treating patients with chronic central serous chorioretinopathy with the drug eplerenone.